- $13.77m
- -$26.50m
- $43.95m
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
Brief: HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
Brief: Poolbeg Pharma Says Co In Talks For Its All-Share Acquisition By Hookipa
Brief: Hookipa Pharma Inc - On November 18 Approved Plan to Reduce Workforce By Approximately 80%
Hookipa Pharma Inc Reports Results For The Quarter Ended September 30: Earnings Summary
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Hookipa Pharma Inc Expected To Post A Loss Of $1.28 A Share: Earnings Preview
Brief: HOOKIPA Pharma Doses First Patients With ESEBA-VEC As Adjuvant Therapy In Phase 2 Investigator Lead Trial For Head & Neck Cancer
Hookipa Pharma Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Hookipa Pharma - May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time
Hookipa Pharma Inc Expected To Post A Loss Of $1.25 A Share: Earnings Preview
Brief: Hookipa Pharma Announces Leadership Changes To Intensify Focus On HB-200
Brief: Hookipa Pharma Announces Effective Date Of 1-For-10 Reverse Stock Split
Brief: Hookipa Pharma Announces First Person Dosed In Phase 1B Clinical Trial Of Hb-500 For The Treatment Of HIV
Brief: Hookipa Pharma Announces Positive Clinical Data To Be Presented At The American Society For Clinical Oncology 2024 Annual Meeting